Can we finally move past the dogma of single station lobectomy only for N2 disease safe resections with better outcomes for patients?

Yeah.

So I think one thing that was cool, there was a session that was really focused on, you know, surgery in the era of immunotherapy and this concept of the immunosurgeon coming into place.

And I kind of like it because it was it was a group of people who had I heard them speak.

Well, when I heard them speak.

few years ago would not have like been so flexible about how we adapt our practice and they really have become very interested about the interplay between biology available therapeutics sequencing timing of surgery extent of surgery all of these components are being discussed in a very forward thinking way, which is exciting, sort of a personal bias here.

And one that is somewhat supported by data is that stage no longer matters.

What did the researchers share about the updates for their non-PATH-CR arm and their PATH-CR arms in the Kino 671?

All right, you want to take this over? Yeah,

sure.

So, OK, so clearly we need to discuss more because nobody is sure what to do in this setting.

These are the stage two data, actually a dedicated stage two manuscript led by Masahiro Tsuboi, who sadly passed away just a couple of months ago.

But what I think is important to note here is that this is HACC8.

If you're stage 2A, so these are the greater than four no negative patients, or 2B, N1 or T3N0 patients, you have equal benefit or almost equal benefit to the addition of perioperative immunotherapy over chemo alone.

You don't really see any difference between stage 2A and stage 2B when you add immunotherapy.

Clear consensus.

All right, you want to take this over? Yeah,

sure.

So, OK, so clearly we need to discuss more because nobody is sure what to do in this setting.

These are the stage two data, actually a dedicated stage two manuscript led by Masahiro Tsuboi, who sadly passed away just a couple of months ago.

But what I think is important to note here is that this is HACC8.

If you're stage 2A, so these are the greater than four no negative patients, or 2B, N1 or T3N0 patients, you have equal benefit or almost equal benefit to the addition of perioperative immunotherapy over chemo alone.

You don't really see any difference between stage 2A and stage 2B when you add immunotherapy.

Clear consensus.

All right, you want to take this over?

Yeah, sure.

So, OK, so clearly we need to discuss more because nobody is sure what to do in this setting.

These are the stage two data, actually a dedicated stage two manuscript led by Masahiro Tsuboi, who sadly passed away just a couple of months ago.

But what I think is important to note here is that this is HACC 8.

If you're stage 2A, so these are the greater than 4 node negative patients, or 2B, N1 or T3N0 patients, you have equal benefit or almost equal benefit to the addition of perioperative immunotherapy over chemo alone.

You don't really see any difference between stage 2A and stage 2B when you add immunotherapy.

Clear consensus.

All right, you want to take this over?

Yeah, sure.

So, OK, so clearly we need to discuss more because nobody is sure what to do in this setting.

These are the stage two data, actually a dedicated stage two manuscript led by Masahiro Tsuboi, who sadly passed away just a couple of months ago.

But what I think is important to note here is that this is HACC 8.

If you're stage 2A, so these are the greater than 4 node negative patients, or 2B, N1 or T3N0 patients, you have equal benefit or almost equal benefit to the addition of perioperative immunotherapy over chemo alone.

You don't really see any difference between stage 2A and stage 2B when you add immunotherapy.

Clear consensus.